ロード中...

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

BACKGROUND: Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic fusion protein, designated anti-MCSP:TRAIL, that is comprised of a melanoma-associated chondroitin sulfate...

詳細記述

保存先:
書誌詳細
主要な著者: de Bruyn, Marco, Rybczynska, Anna A, Wei, Yunwei, Schwenkert, Michael, Fey, Georg H, Dierckx, Rudi AJO, van Waarde, Aren, Helfrich, Wijnand, Bremer, Edwin
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2010
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3000402/
https://ncbi.nlm.nih.gov/pubmed/21092273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-9-301
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!